News

FDA approval paves the way for the jab to roll out across the world. But with funding being slashed, will it get to the ...
Gilead's FDA-approved Yeztugo, a twice-yearly injectable HIV PrEP, showed near-perfect trial efficacy but faces backlash over ...
The US FDA has approved lenacapavir, a biannual injection by Gilead, to prevent HIV, potentially revolutionizing the fight against the epidemic.
FDA Approves Yeztugo as First Twice-Yearly Injectable HIV Prevention Option in the U.S. Clinical Trials Show Near-Perfect ...
Gilead Sciences garnered investor and analyst focus after the U.S. FDA approval of Yeztugo, or lenacapavir, the company’s ...
Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...
On Wednesday, the Food and Drug Administration approved a highly effective, injectable drug to help prevent the transmission ...
The U.S. Food and Drug Administration approved an HIV prevention medication that has been proven highly effective in clinical ...
Men, women, gay, straight – it really just kinds of expands the opportunity for prevention’ Source: Twice-a-year shot to prevent HIV could stop transmission — if people can get it – Zimbabwe News Now ...
The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...
The injectable HIV prevention treatment Yetzugo, made by Gilead Sciences, has received FDA approval, offering a twice-yearly ...